Anti-VEGFA Antibody, clone 1D14 ZooMAb^® Rabbit Monoclonal

Vascular endothelial growth factor A, long form (UniProt: P15692; also known as L-VEGF, Vascular permeability factor, VPF) is encoded by the VEGFA (also known as VEGF) gene (Gene ID: 7422) in human. This gene is a member of the PDGF/VEGF growth factor family. It encodes a heparin-binding protein, which exists as a disulfide-linked homodimer. This growth factor induces proliferation and migration of vascular endothelial cells, and is essential for both physiological and pathological angiogenesis. VEGFA is secreted by tumor cells and other cells exposed to hypoxia or other stimuli, with its localization being predominantly cytoplasmic in endothelial cells. Alternatively spliced transcript variants encoding 17 different isoforms have been described. The most commonly studied isoforms are VEGF121, VEGF165, and VEGF189 (f, d and b, respectively). These isoforms differ in their molecular mass and in biological properties, such as their ability to bind to cell-surface heparan-sulfate proteoglycans. VEGF-A primarily signals through two high-affinity receptor tyrosine kinases, VEGFR1 and VEGFR2, and also interacts with neuropilins as co-receptors. This signaling cascade is critical for endothelial cell proliferation, migration, and survival. This gene is upregulated in many known tumors and its expression is correlated with tumor stage and progression. Elevated levels of this protein are found in patients with POEMS syndrome, also known as Crow-Fukase syndrome. Allelic variants of this gene have been associated with microvascular complications of diabetes 1 (MVCD1), age-related macular degeneration and atherosclerosis. Studies suggest VEGF as a potential biomarker for collateral circulation assessment and heart failure mortality. Disruption of this gene in mice resulted in abnormal embryonic blood vessel formation. This ZooMAb^® recombinant monoclonal antibody, generated by our proprietary technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Shaik, F., et al. (2020). Biomolecules. 10(12); 1673; Florek, K., et al. (2024). Biomedicines. 10;12(5):1055).

ZooMAb^® antibodies represent an entirely new generation of recombinant monoclonal antibodies. Each ZooMAb^® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb^® antibodies are reliably available and ready to ship when you need them.

KLH-conjugated linear peptide corresponding to 20 amino acids from the N-terminal region of short isoforms of human VEGFA.

Quality Control Testing

Evaluated by Western Blotting in U-87 MG cell lysate.

Western Blotting Analysis: A 1:1,000 dilution of this antibody detected VEGFA protein in U-87 MG cell lysate.

Tested Applications

Western Blotting Analysis: A 1:1,000 dilution of this antibody detected N-terminal His6-ABP fusion-tagged recombinant fragment of human VEGFA.

Affinity Binding Assay: A representative lot of this antibody bound VEGFA recombinant protein with at least ten thousand-fold (10,000X) higher affinity than with non-specific control protein.

Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected VEGFA in human kidney and human thyroid tissue sections.

Note: Actual optimal working dilutions must be determined by end user as specimens and experimental conditions may vary with the end user.

Clone 1D14 is a ZooMAb^® recombinant rabbit monoclonal antibody that specifically detects VEGFA. It targets an epitope within 20 amino acids from the N-terminal region of short isoforms of VEGFA.

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.

300 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.